Jérémy Béguin, et al. Molecular Therapy Oncolytics, September 2020 – Read the article Publication
Category: 2020
Safety studies and viral shedding of intramuscular administration of oncolytic vaccinia virus TG6002 in healthy beagle dogs
Jérémy Béguin, et al. BMC Vet Res., August 25 2020 – Read the article Publication
Transgene Receives $22.2 million from the Sale of Part of its Minority Stake in Tasly BioPharmaceuticals
20200804 Transgene – Partial sale Tasly Shares EN
Transgene Reports Results from Clinical Study of TG4001 in Combination with Avelumab in Advanced HPV-Positive Cancers
CP TG4001+avelumab EN – Vdef-
Transgene and Hypertrust Patient Data Care announce successful go-live of the world’s first blockchain solution for clinical trials of personalized healthcare
20200709 PR Hypertrust Transgene EN
Design of an Innovative Model to Improve Anticancer Therapeutic Treatment Based on a Vascularized 3D Organoids Derived from Patients’ Lung Tumors for the Purpose of Precision Medicine
Poster EUROoCS H. Le et al. EUROoCS 2020 Download the poster here Poster Presentation
Performance of neoantigen prediction for the design of TG4050, a patient specific neoantigen cancer vaccine
AACR2020 myvac B. Mallone et al. AACR 2020 Download the poster here Poster Presentation
BT-001, an oncolytic Vaccinia virus armed with a Treg-depletion-optimized recombinant human anti-CTLA4 antibody and GM-CSF to target the tumor microenvironment
AACR2020-BT-001 Jean-Baptiste Marchand et al. AACR 2020 Download the poster here Poster Presentation
Oncolytic Vaccinia Virus expressing Cytidine Deaminase induces DNA damage and shows potent anti-tumor effects
AACR2020 6010 J. Foloppe et al. AACR 2020 Download the poster here Poster Presentation
Transgene’s and BioInvent’s BT-001 achieves outstanding tumor cure rates in preclinical models
20200622b – BT-001_AACR poster EN